Elite’s deep relationship to the domestic industry makes us experts in finding high-value China healthcare investments and negotiating with Chinese medical companies.
What We Do
Growth Equity Capital
Financing growth is a major challenge that all businesses face at some point in their development. With unparalleled relationships, perspectives and insights on the Chinese pharmaceutical, medical device, and healthcare system, Elite can help our clients to secure growth equity that fits their specific needs at optimal terms. Elite specializes in raising growth equity capital for mid- to late-stage (including pre-IPO rounds), profitable or near-term profitable, private companies to fund organic growth, acquisitions, and/or shareholder liquidity.
Sell side mandate:
Elite is an ideal advisor for selling minority or majority stakes of China medical businesses to financial investors (venture capital, private equity, family offices, institutional investors, etc.) or interested strategic companies. Elite maximizes the value of our clients’ businesses by utilizing our industry knowledge to identify potential buyers who most value the company. Elite facilitates the negotiation process by capitalizing on our team in China and our extensive history in the industry. Our structured process helps our clients to obtain superior valuation, terms and certainty-to-close.
Buy side mandate:
ECA’s in-depth knowledge of local markets and the needs of prospective sellers can help our clients identify and execute acquisitions suited to their purpose. ECA can introduce M&A targets, commercial deals, carve-outs of products & franchises. From initiation of discussions and synergy analysis through management of the due diligence process and final negotiations, ECA’s unique credibility, wide reach, proven transaction expertise, and ability to provide post-deal integration assistance will help our clients to bring our clients from initial contact through closing.
Unique perspectives and insights on the Chinese pharmaceutical, medical device, and healthcare system
Extensive network of connections with strategic players and financial players in the Chinese pharmaceutical, healthcare, and medical device industry
Can provide clients with credibility, structured process, and proven transaction expertise
Elite Consulting facilitates a $25 million investment in Dihon Pharmaceutical for Hony Capital
Elite Consulting completes $212 million acquisition of Guangdong Techpool Biopharmaceutical Ltd. to Nycomed Holdings